Saturday, 22 June 2013
Dapagliflozin - vanishes new drug for diabetes therapy on the German market?
Press Release: German Diabetic Association (DDB)
German Confederation urges diabetics receiving effective treatment options
Diabetes patients are modern drugs available that reduce blood sugar effectively today. However, for reasons of cost fall more and more diabetes medications from the refund. The latest example: "dapagliflozin" (trade name: "Forxiga"). According to a decision of the Federal Joint Committee (G-BA) in June of SGLT-2 inhibitor has no additional benefit compared to conventional preparations. The German Diabetic Association (DDB) considers this decision - especially in international comparison - for "totally inconclusive" and fears a health risk to the patient.
Dapagliflozin is the first compound of a new group of diabetes drugs, the SGLT-2 inhibitors. It follows the principle of action, that more sugar is excreted in the urine, so can blood sugar, blood pressure and body weight reduction.
metformin like medication from the kitchen
Onion can increase muscle performance, reduce coffee, to a certain extent, the skin cancer risk. The food as medicine.
MerkenAAA Text Size Print Send Comment
FROM THE ARCHIVES: Diabetes: Even doctors trivialize (28/09/2009)
Some even turn up at the idea of "healthy eating" nose. Because they combine healthy with bland. Far from it. The Onion example, may well say of any taste. But the plant is something of a health-trades. Only because of their high content of flavonoid quercetin. "It is the only natural substance that mitochondria, so multiply the power plants of our cells, and thus increase the power of the muscles can," says Markus Metka, gynecologist and President of the Austrian anti-aging society.
Health system: how to proceed?
It is high time for change: The burning questions about the future of health care will be on 24 Discussed at the September Med & Care Conference in Graz by experts.
Read more »
MerkenAAA Text Size Print Send Comment
FROM THE ARCHIVES: Diabetes: Even doctors trivialize (28/09/2009)
Some even turn up at the idea of "healthy eating" nose. Because they combine healthy with bland. Far from it. The Onion example, may well say of any taste. But the plant is something of a health-trades. Only because of their high content of flavonoid quercetin. "It is the only natural substance that mitochondria, so multiply the power plants of our cells, and thus increase the power of the muscles can," says Markus Metka, gynecologist and President of the Austrian anti-aging society.
Health system: how to proceed?
It is high time for change: The burning questions about the future of health care will be on 24 Discussed at the September Med & Care Conference in Graz by experts.
Read more »
Additional benefit of lixisenatide not used
Lixisenatide is approved for the treatment of diabetes mellitus type second IQWiG has now checks whether this new drug compared with the previous standard therapy offers an additional benefit.
Lixisenatide (Lyxumia ®) has been approved in February 2013, when these do not provide adequate along with diet and exercise increased blood sugar levels for the treatment of type 2 diabetes mellitus in combination with oral hypoglycaemic agents or basal insulin. The Institute for Quality and Efficiency in Health Care (IQWiG) has reviewed an early benefit assessment pursuant pharmaceutical market Restructuring Act (AMNOG) whether this new drug compared with the previous standard therapy offers an additional benefit. However, from the dossier, such an additional benefit can not be inferred because the manufacturer has submitted data suitable for any of the possible applications of lixisenatide.
Lixisenatide (Lyxumia ®) has been approved in February 2013, when these do not provide adequate along with diet and exercise increased blood sugar levels for the treatment of type 2 diabetes mellitus in combination with oral hypoglycaemic agents or basal insulin. The Institute for Quality and Efficiency in Health Care (IQWiG) has reviewed an early benefit assessment pursuant pharmaceutical market Restructuring Act (AMNOG) whether this new drug compared with the previous standard therapy offers an additional benefit. However, from the dossier, such an additional benefit can not be inferred because the manufacturer has submitted data suitable for any of the possible applications of lixisenatide.
Subscribe to:
Posts (Atom)